Web Exclusives

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.

Hypnosis and Its Use in Cancer Treatment

Hypnosis and Its Use in Cancer Treatment

A cursory look at hypnosis and where it may be used to offer an alternative and side-effect-free management of several aspects of care that can be beneficial to patients with cancer.

Cancer Mortality Rates Continue to Drop in the United States

Cancer Mortality Rates Continue to Drop in the United States

Cancer mortality rates in the United States have dropped, according to a new ACS report.

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

Menopause-specific QoL Changes Associated With Chemoprevention Nonadherence

A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Diarrhea Common But Manageable With Pertuzumab-containing Regimens

Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.

Perceived Breast Density May Influence Single Read Suitability

Perceived Breast Density May Influence Single Read Suitability

Features mainly linked to mammographic breast density are key in influencing a classification of normal.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs